Login / Signup

Sustained effects of rapidly acting antidepressants require BDNF-dependent MeCP2 phosphorylation.

Ji-Woon KimAnita E AutryElisa S NaMegumi AdachiCarl BjörkholmEge T KavalaliLisa M Monteggia
Published in: Nature neuroscience (2021)
The rapidly acting antidepressants ketamine and scopolamine exert behavioral effects that can last from several days to more than a week in some patients. The molecular mechanisms underlying the maintenance of these antidepressant effects are unknown. Here we show that methyl-CpG-binding protein 2 (MeCP2) phosphorylation at Ser421 (pMeCP2) is essential for the sustained, but not the rapid, antidepressant effects of ketamine and scopolamine in mice. Our results reveal that pMeCP2 is downstream of BDNF, a critical factor in ketamine and scopolamine antidepressant action. In addition, we show that pMeCP2 is required for the long-term regulation of synaptic strength after ketamine or scopolamine administration. These results demonstrate that pMeCP2 and associated synaptic plasticity are essential determinants of sustained antidepressant effects.
Keyphrases
  • major depressive disorder
  • pain management
  • binding protein
  • bipolar disorder
  • newly diagnosed
  • type diabetes
  • randomized controlled trial
  • dna methylation
  • gene expression
  • adipose tissue
  • genome wide